| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Repurchases of common stock | 3,971 | 3,971 |
| Net cash used in financing activities | -5,272 | -5,259 |
| Exchange rate impact on cash | 151 | 453 |
| Decrease in cash and cash equivalents | 831 | -3,992 |
| Cash and cash equivalents at beginning of period | 57,159 | - |
| Cash and cash equivalents at end of period | 57,990 | - |
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)